{"name":"Taizhou Mabtech Pharmaceutical Co.,Ltd","slug":"taizhou-mabtech-pharmaceutical-co-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"oncology","drugs":[{"name":"CMAB015","genericName":"CMAB015","slug":"cmab015","indication":"Other","status":"phase_3"},{"name":"CMAB007","genericName":"CMAB007","slug":"cmab007","indication":"Other","status":"phase_3"},{"name":"CMAB009","genericName":"CMAB009","slug":"cmab009","indication":"Other","status":"phase_3"},{"name":"New technology Enlituo","genericName":"New technology Enlituo","slug":"new-technology-enlituo","indication":"Other","status":"phase_1"}]},{"name":"Respiratory","slug":"respiratory","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Xolair","genericName":"Xolair","slug":"xolair","indication":"Asthma","status":"marketed"}]}],"pipeline":[{"name":"CMAB015","genericName":"CMAB015","slug":"cmab015","phase":"phase_3","mechanism":"CMAB015 is a monoclonal antibody that targets and inhibits a specific immune checkpoint or tumor-associated antigen to enhance anti-tumor immunity.","indications":[],"catalyst":""},{"name":"CMAB007","genericName":"CMAB007","slug":"cmab007","phase":"phase_3","mechanism":"CMAB007 is a monoclonal antibody that targets and inhibits a specific immune checkpoint or tumor-associated antigen to enhance anti-tumor immunity.","indications":[],"catalyst":""},{"name":"CMAB009","genericName":"CMAB009","slug":"cmab009","phase":"phase_3","mechanism":"CMAB009 is a monoclonal antibody targeting a specific immune checkpoint or tumor-associated antigen to modulate immune response against cancer cells.","indications":[],"catalyst":""},{"name":"New technology Enlituo","genericName":"New technology Enlituo","slug":"new-technology-enlituo","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"Xolair","genericName":"Xolair","slug":"xolair","phase":"marketed","mechanism":"Ig epsilon chain C region","indications":["Asthma","Chronic idiopathic urticaria","Seasonal allergic rhinitis"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxQd1BSdGNva0tpWmhrQ0lfb0F3M3JGX093cTRZczBURnhXVmkwU1VFenJVcndjM1o5X1dVc3YtekpmczhDdHVTSUJ1V3BGdUpvNHdyZElfZjh3V291MEhiYWFqNHp6NDRJZE12ZmRIR1EtajFndjJEUjVXYjJQNENUcnlvZ3FQR21mRHI5Uk9hNFc4U0RZc0Z1bmNB?oc=5","date":"2026-04-07","type":"regulatory","source":"openPR.com","summary":"Chronic Plaque Psoriasis Market Size is to Show Remarkable Growth Trends from 2024 to 2034, estimates DelveInsight - openPR.com","headline":"Chronic Plaque Psoriasis Market Size is to Show Remarkable Growth Trends from 2024 to 2034, estimates DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiakFVX3lxTE5RckxOb1lQbWJoU0JxRFRHT0JsOUwtNDBySFYzeUZMNEpWM1EyaWxRMW1zLTJxZlczSU5FRzBGajVGbTUzTlFjZExoNVlUQVFQMDdtbGtnWXZjLXRkNGZreEFpelh3dkE0OEE?oc=5","date":"2022-10-04","type":"patent","source":"Wiley Online Library","summary":"Oncology biosimilars: New developments and future directions - Bachu - 2022 - Cancer Reports - Wiley Online Library","headline":"Oncology biosimilars: New developments and future directions - Bachu - 2022 - Cancer Reports","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxPd0RLdHNGRE9UUGZBbEpmN0NUa0JNaU16eVhXWGpOc1BSZHpCZ0xmd2dnQy0xWXRoTWFBRW5LWFhQUGF0MEZmRTM4SDBKc3I3Xy1DZUJRUjB2OXVDQ28tY0RSWGpJY200M1AyV3FtQjhCSDBUSUJ3RW5aWVVqRWs0Nl85cV9DdW1xZW0yd3E1Zw?oc=5","date":"2022-04-04","type":"pipeline","source":"Frontiers","summary":"Identification, Efficacy, and Stability Evaluation of Succinimide Modification With a High Abundance in the Framework Region of Golimumab - Frontiers","headline":"Identification, Efficacy, and Stability Evaluation of Succinimide Modification With a High Abundance in the Framework Re","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxORnpZVkIwSTEtZ3BIUzAxaHE2RXJmTXl4NF9BVEVqQW5TM181RE5iSVRvOVpQdnYzYU9xRUxHYm4yN0lYSGlTMEwzWTZWSjRjVVhBWExHSDNBR01KZHF4dVRkclAwV3J1UUJ1dzJqTlRyN1FyZXR4ZWowN1NPSkN6MTZBNzd6bnNuYnlZYVdzSVBPSVE?oc=5","date":"2022-01-23","type":"patent","source":"Frontiers","summary":"Pharmacokinetics, Pharmacodynamics, Safety and Immunogenicity of CMAB807, a New Denosumab Biosimilar, in Healthy Chinese Subjects - Frontiers","headline":"Pharmacokinetics, Pharmacodynamics, Safety and Immunogenicity of CMAB807, a New Denosumab Biosimilar, in Healthy Chinese","sentiment":"neutral"}],"patents":[],"drugCount":5,"phaseCounts":{"phase_3":3,"phase_1":1,"marketed":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}